Role Definition
| Field | Value |
|---|---|
| Job Title | Toxicologist (mapped to SOC 19-1099, Life Scientists All Other) |
| Seniority Level | Mid-Level (5-12 years, PhD or MSc + substantial experience) |
| Primary Function | Studies the adverse effects of chemical, physical, and biological agents on living organisms. Conducts risk assessments for pharmaceuticals, industrial chemicals, and environmental contaminants. Designs and interprets GLP and non-GLP toxicology studies. Writes regulatory submissions (IND, NDA, REACH dossiers, EPA registrations). Determines NOAELs, BMDLs, and reference doses. Reviews literature and applies weight-of-evidence methodologies. Collaborates with regulatory affairs, clinical teams, and external CROs. Works in pharma (drug safety), chemical industry (REACH/EPA compliance), government agencies (FDA, EPA), or forensic settings. |
| What This Role Is NOT | Not a lab technician (executes protocols under supervision -- lower autonomy, lower zone). Not an epidemiologist (population-level disease patterns -- SOC 19-1041, scored 48.6 Green). Not a clinical pharmacologist (drug dosing in patients). Not a computational chemist (purely in silico -- different skill profile). Not a medical scientist (broader disease research -- SOC 19-1042, scored 54.5 Green). |
| Typical Experience | PhD in toxicology, pharmacology, or related biomedical science (5-7 years), plus 3-5 years post-doctoral or industry experience. Many hold or pursue DABT (Diplomate of the American Board of Toxicology) certification. Some enter with MSc + 8-12 years of progressive experience. |
Seniority note: Junior/lab-based toxicologists (0-4 years, executing study protocols, data collection) would score Yellow (~40-43) due to higher proportion of routine analytical tasks and weaker goal-setting autonomy. Senior regulatory toxicologists with signatory authority and strategic oversight would score higher Green (~55-60) due to stronger accountability, judgment, and institutional influence.
- Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 1 | Some toxicologists conduct or oversee lab work (tissue pathology review, necropsy observations, sample handling), but the mid-level role is predominantly desk-based -- writing risk assessments, interpreting data, and reviewing study reports. Physical lab work is structured and largely delegable. |
| Deep Interpersonal Connection | 1 | Regular interaction with regulatory agencies (FDA pre-IND meetings, ECHA queries), cross-functional collaboration with clinical teams, medical monitors, and CROs. Professional relationships matter for regulatory negotiations but trust is not the core value proposition. |
| Goal-Setting & Moral Judgment | 2 | Makes high-stakes judgment calls: determining safe starting doses for first-in-human trials, interpreting ambiguous toxicology findings, deciding whether a chemical meets safety thresholds for registration. Regulatory risk assessments require expert opinion where no formula suffices. However, mid-level toxicologists typically work within defined regulatory frameworks (ICH, OECD guidelines) rather than setting entirely novel direction. |
| Protective Total | 4/9 | |
| AI Growth Correlation | 1 | AI adoption creates modest additional demand for toxicologists who can validate computational predictions, interpret QSAR/in silico outputs, and bridge computational and experimental toxicology. The $636M AI predictive toxicology market (2025) creates new interpretive work, not displacement. |
Quick screen result: Protective 4/9, weak positive correlation. Likely Yellow or borderline Green -- proceed to task analysis.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Regulatory risk assessment writing & scientific interpretation | 25% | 2 | 0.50 | AUGMENTATION | Core value: interpreting toxicology data in regulatory context, determining NOAELs/BMDLs, writing integrated summaries for IND/NDA/REACH submissions. AI drafts sections and synthesises data, but the toxicologist must apply professional judgment to ambiguous findings and bear accountability for safety conclusions that determine whether drugs enter human trials. |
| Study design & protocol development (GLP/non-GLP) | 20% | 2 | 0.40 | AUGMENTATION | Designing toxicology study programmes -- selecting species, dose levels, endpoints, study duration -- requires deep domain expertise and regulatory awareness. AI can suggest standard designs, but non-standard findings demand bespoke protocol modifications that require professional judgment. |
| Data analysis & interpretation (dose-response, toxicokinetics) | 15% | 3 | 0.45 | AUGMENTATION | AI handles significant sub-workflows: statistical modelling, dose-response curve fitting, PK/TK analysis, benchmark dose modelling. The toxicologist leads interpretation -- distinguishing adaptive from adverse effects, assessing biological significance vs statistical significance, and determining human relevance of animal findings. |
| Literature review, weight-of-evidence & expert opinion | 15% | 3 | 0.45 | AUGMENTATION | AI tools (Elicit, Semantic Scholar, Consensus) synthesise literature rapidly. Weight-of-evidence assessment -- integrating in vivo, in vitro, computational, and epidemiological data into a coherent risk narrative -- requires expert judgment. AI accelerates the gathering; the toxicologist performs the synthesis and draws conclusions. |
| Cross-functional collaboration (regulatory, clinical, management) | 10% | 2 | 0.20 | AUGMENTATION | Advising regulatory affairs on submission strategy, consulting with clinicians on safety monitoring plans, presenting findings to management and regulatory agencies. Human communication and professional credibility required. |
| GLP study oversight & CRO management | 10% | 2 | 0.20 | AUGMENTATION | Monitoring contract research organisations conducting GLP studies. Reviewing draft reports, auditing data integrity, ensuring protocol compliance. Regulatory accountability requires human oversight -- GLP regulations mandate study director sign-off by qualified personnel. |
| Computational tox / in silico screening (QSAR, read-across) | 5% | 4 | 0.20 | AUGMENTATION | QSAR models, OECD Toolbox, Derek Nexus, and AI-driven predictive platforms can screen chemicals for mutagenicity, carcinogenicity, and organ toxicity. Growing but still a small fraction of the mid-level toxicologist's workload. AI performs the prediction; the toxicologist validates applicability domain and interprets results in regulatory context. |
| Total | 100% | 2.40 |
Task Resistance Score: 6.00 - 2.40 = 3.60/5.0
Displacement/Augmentation split: 0% displacement, 100% augmentation, 0% not involved.
Reinstatement check (Acemoglu): AI creates substantial new tasks: validating QSAR/in silico predictions against experimental data, interpreting AI-generated adverse outcome pathway (AOP) analyses, auditing computational toxicology outputs for regulatory submissions, serving as the expert bridge between AI predictions and regulatory acceptance. The computational toxicology market ($636M in 2025, projected $3.9B by 2032) creates interpretive and validation work that requires trained toxicologists.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 0 | BLS projects 3-4% growth for Life Scientists All Other (SOC 19-1099) 2024-2034 -- average, not exceptional. Toxicology is a small sub-population (~7,800 in the broader SOC category with ~400 openings/year). Pharma demand for toxicologists is stable but not surging. Computational toxicology roles growing but from a small base. |
| Company Actions | 1 | Pharma companies expanding AI-augmented safety assessment teams. No evidence of AI-driven toxicologist layoffs. FDA and EPA actively promoting New Approach Methodologies (NAMs) that create work for toxicologists who can interpret computational outputs. CROs growing their toxicology practices. Regulatory push to reduce animal testing creates demand for toxicologists skilled in alternative methods. |
| Wage Trends | 0 | BLS median for Life Scientists All Other ~$87,800. Toxicologists in pharma industry typically earn $100K-$160K at mid-level. DABT-certified toxicologists command premiums. Wages tracking inflation -- stable but not surging. Computational toxicology skills increasingly command premiums. |
| AI Tool Maturity | 0 | Production tools augment but don't replace: Derek Nexus (mutagenicity prediction), OECD QSAR Toolbox (read-across), Schrodinger Suite (ADMET prediction), EPA ToxCast/Tox21 (high-throughput screening). Classical ML dominates (56% market share). Tools require expert interpretation and validation -- regulatory agencies will not accept unvalidated computational predictions. AI predictive toxicology market at $636M (2025) growing rapidly. |
| Expert Consensus | 1 | Universal consensus: AI augments toxicologists, does not displace them. PubMed Central (2026): regulatory validation by experts remains essential. FDA guidance emphasises transparency and validation for computational models. OECD promotes AI-driven NAMs while mandating human expert review. No credible source predicts toxicologist displacement -- the consensus is transformation of workflows, not elimination of roles. |
| Total | 2 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | GLP regulations mandate qualified study directors with documented expertise. FDA requires qualified toxicologists for IND submissions -- human sign-off on safety assessments that determine whether drugs enter human trials. EPA requires qualified scientists for pesticide registration toxicology packages. DABT certification (voluntary but widely expected) requires PhD + 3 years + board examination. No regulatory pathway for AI to serve as study director or signatory toxicologist. |
| Physical Presence | 0 | Mid-level toxicologists are predominantly desk-based. Study oversight and occasional lab visits can be conducted remotely or delegated. No significant physical presence barrier. |
| Union/Collective Bargaining | 0 | Scientists are not unionised in the US. No collective bargaining protections. |
| Liability/Accountability | 2 | Toxicologists bear direct professional accountability for safety assessments. A flawed risk assessment that leads to patient harm in clinical trials or public exposure to unsafe chemicals creates personal and organisational liability. The study director on a GLP study is legally accountable for the integrity and interpretation of the data. FDA and EPA enforcement actions target individuals, not algorithms. |
| Cultural/Ethical | 1 | Regulatory agencies, pharma companies, and the public expect human expert judgment on chemical and drug safety. FDA advisory committees and regulatory reviewers engage with human toxicologists, not AI systems. Growing acceptance of computational tools as supporting evidence, but cultural expectation of human expert accountability for final safety determinations remains strong. |
| Total | 5/10 |
AI Growth Correlation Check
Confirmed +1 (Weak Positive). AI adoption creates modest additional demand for toxicologists in three ways: (1) computational toxicology growth requires trained toxicologists to validate AI predictions and ensure regulatory acceptability; (2) the regulatory push to reduce animal testing (FDA Modernization Act 2.0, EU 3Rs directives) creates demand for toxicologists skilled in NAMs and in silico interpretation; (3) AI-augmented drug discovery pipelines generate more drug candidates faster, each requiring toxicological evaluation. Not Accelerated Green -- the role does not exist because of AI. But AI growth creates incremental demand for toxicologists who can operate at the human-AI interface.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.60/5.0 |
| Evidence Modifier | 1.0 + (2 x 0.04) = 1.08 |
| Barrier Modifier | 1.0 + (5 x 0.02) = 1.10 |
| Growth Modifier | 1.0 + (1 x 0.05) = 1.05 |
Raw: 3.60 x 1.08 x 1.10 x 1.05 = 4.4906
JobZone Score: (4.4906 - 0.54) / 7.93 x 100 = 49.8/100
Zone: GREEN (Green >= 48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 35% |
| AI Growth Correlation | 1 |
| Sub-label | Green (Transforming) -- >= 20% task time scores 3+, AIJRI >= 48 |
Assessor override: None -- formula score accepted. The 49.8 is borderline (1.8 points above Green/Yellow boundary) but accurately reflects the role's position: strong task resistance and regulatory barriers narrowly secure Green classification. The barrier-dependent nature is flagged in Step 7.
Assessor Commentary
Score vs Reality Check
The 49.8 AIJRI places this role just 1.8 points above the Green/Yellow boundary -- the thinnest Green margin in the Life Sciences cohort. The classification is barrier-dependent: removing barriers (set to 0/10) drops the score to 44.7 Yellow. This is appropriate -- regulatory accountability (GLP study director mandates, FDA/EPA signatory requirements) is a genuine structural barrier that prevents AI execution even when technically capable. Unlike physicality barriers that erode with robotics, regulatory accountability barriers are legal constructs that require legislative change to remove. Compare to Medical Scientist (54.5) -- medical scientists benefit from stronger evidence (+5 vs +2) and deeper creative research autonomy. Compare to Chemist (38.4 Yellow) -- chemists have weaker barriers (3/10 vs 5/10) and more routine analytical work. The toxicologist sits between these anchors, which is calibrated correctly.
What the Numbers Don't Capture
- Pharma vs chemical industry divergence. Pharma toxicologists working on drug safety (IND/NDA submissions) operate under stronger regulatory accountability and face less displacement risk than industrial toxicologists doing routine REACH compliance work. The REACH compliance sub-population is more exposed to AI-driven screening and read-across automation.
- Computational toxicology as threat and opportunity. The $636M AI predictive toxicology market is growing at ~30% CAGR. Toxicologists who master computational tools become more valuable; those who resist them become less relevant. The score captures the average, but the variance within the profession is widening.
- Small occupation size. Toxicology is a niche profession within the ~7,800 Life Scientists All Other SOC category. Small sample sizes make BLS projections less reliable than for larger occupations. Individual employer decisions have outsized impact.
- Animal testing phase-out trajectory. The FDA Modernization Act 2.0 (2022) removed the requirement for animal testing in drug development. As in silico and in vitro methods mature, the balance of toxicologist work shifts from overseeing animal studies to interpreting computational and alternative method data -- a transformation that preserves the role but changes its daily content.
Who Should Worry (and Who Shouldn't)
Mid-level toxicologists in drug safety and regulatory roles should not worry. If you write risk assessments for IND/NDA submissions, design toxicology study programmes, and bear signatory accountability for safety conclusions, you are doing work that AI cannot be permitted to perform autonomously -- regulatory frameworks mandate human expert judgment. Most protected: DABT-certified regulatory toxicologists in pharma with signatory authority on IND submissions. More exposed: Toxicologists doing routine REACH compliance data compilation, literature-based risk assessments without novel interpretation, or purely computational screening work. These sub-populations are closer to Yellow territory. The single biggest factor: whether you interpret and bear accountability for safety conclusions, or whether you primarily compile and format data for someone else to sign off on. The signatory toxicologist is protected by law. The data-compilation toxicologist is exposed to AI automation.
What This Means
The role in 2028: Toxicologists will use AI as standard infrastructure -- QSAR models for screening, AI-driven literature synthesis for weight-of-evidence assessments, automated dose-response modelling, and computational AOP analysis. In silico methods will be embedded in every regulatory submission as supporting evidence. But the toxicologist still designs study programmes, interprets ambiguous findings, determines human relevance of animal data, bears signatory accountability for safety conclusions, and navigates regulatory negotiations with FDA and EPA reviewers.
Survival strategy:
- Develop computational toxicology fluency -- learn QSAR interpretation, PBPK modelling, and how to critically evaluate AI-generated toxicity predictions. The toxicologist who bridges wet lab and computational science is most valuable.
- Pursue or maintain DABT certification -- it formalises the expertise barrier and signals regulatory-grade competence to employers and agencies.
- Position yourself at the AI-regulatory interface -- become the expert who translates computational toxicology outputs into regulatory-acceptable risk assessments, as agencies increasingly demand NAMs expertise.
Timeline: 10-15 years. Constrained by GLP regulatory mandates for qualified human study directors, FDA/EPA requirements for human expert accountability on safety assessments, the expanding drug development pipeline generating more compounds requiring toxicological evaluation, and the decade-plus timeline for regulatory frameworks to evolve.
